Bioxytran (BIXT) EBITDA (2010 - 2026)
Bioxytran (BIXT) posted EBITDA of -$1.9 million for Q1 2026, down 218.31% sequentially from -$607285.0 in Q4 2025, and down 275.25% YoY from $1.1 million in Q1 2025.
Bioxytran (BIXT) EBITDA (2010 - 2026) Analysis & Trends
Bioxytran has reported EBITDA for 17 years, with the latest figure at -$1.9 million in Q1 2026.
- Quarterly EBITDA fell 275.25% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.3 million (down 66.43% YoY) and the FY2025 annual result came in at -$1.8 million, up 17.12% from the prior year.
- EBITDA retreated to -$1.9 million in Q1 2026 per BIXT's latest filing, from -$607285.0 in the prior quarter.
- Over five years, EBITDA peaked at $14225.0 in Q3 2022 and troughed at -$1.9 million in Q1 2026.
- A 5-year average of -$719728.6 and a median of -$609322.0 in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2023: EBITDA surged 102.6% in 2022, then slumped 7027.7% in 2023.
- Over 5 years, EBITDA stood at -$1.1 million in 2022, then rose by 8.01% to -$1.0 million in 2023, then soared by 51.5% to -$488313.0 in 2024, then fell by 24.36% to -$607285.0 in 2025, then sank by 218.31% to -$1.9 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$1.9 million, -$607285.0, and -$496005.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | -654,600.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.93 Mn |
| Dec 31, 2025 | -607,285.00 |
| Sep 30, 2025 | -496,005.00 |
| Jun 30, 2025 | -224,079.00 |
| Mar 31, 2025 | -515,142.00 |
| Dec 31, 2024 | -488,313.00 |
| Sep 30, 2024 | -346,204.00 |
| Jun 30, 2024 | -609,322.00 |
| Mar 31, 2024 | -779,229.00 |
| Dec 31, 2023 | -1.01 Mn |
| Sep 30, 2023 | -985,465.00 |
| Jun 30, 2023 | -1.06 Mn |
| Mar 31, 2023 | -750,242.00 |
| Dec 31, 2022 | -1.09 Mn |
| Sep 30, 2022 | 14,225.00 |
| Jun 30, 2022 | -537,224.00 |
| Mar 31, 2022 | -819,106.00 |
| Dec 31, 2021 | -935,964.00 |
| Sep 30, 2021 | -547,243.00 |
| Jun 30, 2021 | -1.04 Mn |